MediWound (NASDAQ:MDWD) Upgraded to Sell by StockNews.com

MediWound (NASDAQ:MDWD) was upgraded by equities researchers at StockNews.com to a “sell” rating in a report issued on Wednesday.

Separately, HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of MediWound in a report on Friday, March 22nd.

MediWound Trading Down 6.3 %

NASDAQ MDWD traded down $1.20 on Wednesday, hitting $17.75. 70,045 shares of the company’s stock traded hands, compared to its average volume of 68,015. The firm has a market capitalization of $168.48 million, a PE ratio of -23.05 and a beta of 0.81. MediWound has a 1-year low of $7.10 and a 1-year high of $19.86. The firm’s 50-day moving average price is $16.27 and its two-hundred day moving average price is $12.62.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. The company had revenue of $5.34 million for the quarter, compared to the consensus estimate of $5.33 million. MediWound had a negative return on equity of 20.22% and a negative net margin of 35.94%. On average, research analysts anticipate that MediWound will post -1.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MediWound

Large investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC lifted its position in shares of MediWound by 241.6% during the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after buying an additional 93,705 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of MediWound during the 1st quarter valued at approximately $427,000. Silverberg Bernstein Capital Management LLC lifted its position in shares of MediWound by 7.8% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock valued at $1,214,000 after buying an additional 6,200 shares in the last quarter. Yelin Lapidot Holdings Management Ltd. lifted its position in shares of MediWound by 45.7% during the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after buying an additional 39,348 shares in the last quarter. Finally, Sargent Investment Group LLC lifted its position in shares of MediWound by 7.0% during the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after buying an additional 7,125 shares in the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.